Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD7 Phase 3 randomized trial

BACKGROUND: Baricitinib is an oral, selective, reversible Janus kinase 1/2 inhibitor approved in the European Union and Japan and under investigation in the United States for treatment of atopic dermatitis (AD). OBJECTIVES: To evaluate the impact of baricitinib plus background topical corticosteroid...

Descripción completa

Detalles Bibliográficos
Autores principales: Wollenberg, A., Nakahara, T., Maari, C., Peris, K., Lio, P., Augustin, M., Silverberg, J.I., Rueda, M.J., DeLozier, A.M., Pierce, E., Yang, F.E., Sun, L., Ball, S., Tauber, M., Paul, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Allergy and Eczema
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251919/
https://www.ncbi.nlm.nih.gov/pubmed/33834521
http://dx.doi.org/10.1111/jdv.17278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251919/
https://www.ncbi.nlm.nih.gov/pubmed/33834521
http://dx.doi.org/10.1111/jdv.17278

Ejemplares similares